BioMérieux
{{Short description|French multinational biotechnology company}}
{{lowercase title}}
{{Expand French|bioMérieux|date=August 2015|topic=}}
{{Infobox company
| name = bioMérieux SA
| logo = BioMérieux logo.svg
| type = Société Anonyme
| industry = Biotechnology
| products = in vitro diagnostics
| traded_as = {{EuronextParis|BIM|FR0013280286|XPAR}}
CAC Next 20 component
| ISIN = {{ISIN|sl=n|pl=y|FR0013280286}}
| foundation = {{start date and age|1963}}
| founder = Dr Alain Mérieux
| key_people = Pierre Boulud (CEO)
Alexandre Mérieux (Chairman)
Dr Marcel Mérieux
Dr Charles Mérieux
| location = Marcy-l'Étoile, France
| area_served = Worldwide
| revenue = €3.1 billion (2020)
| num_employees = 12,800 (2020)
| homepage = {{URL|http://www.biomerieux.com}}
}}
bioMérieux SA is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, close to Lyon. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.{{Cite web|last=|first=|date=|title=Company Profile|url=https://www.euronext.com/en/products/equities/FR0010096479-XPAR/company-information|url-status=live|archive-url=https://web.archive.org/web/20171107012815/https://www.euronext.com/en/products/equities/FR0010096479-XPAR/company-information |archive-date=2017-11-07 |access-date=|website=Euronext}}
bioMérieux provides diagnostic solutions (reagents, instruments, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.{{Cite web|title=Stocks|url=https://www.bloomberg.com/markets/stocks|access-date=2020-11-03|website=Bloomberg.com|language=en}} bioMérieux is listed on the Euronext Paris stock exchange (BIM – ISIN: FR0013280286).
Revenue
bioMérieux had revenues of €3.1 billion as of 2020 with 93% of sales occurring outside France.{{Cite web|title=2020 Financial Results|url=https://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_financial_results_fy_2020.pdf|website=bioMérieux Corporate Website|language=en}}
History
In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux.{{Cite web|title=A PASTEURIAN TRADITION|url=https://www.institut-merieux.com/en/deep-rooted-history/a-pasteurian-tradition/|access-date=2021-07-27|website=Institut Merieux|language=en}} In 1963, Alain Mérieux founded BD Mérieux, of which he became majority shareholder in 1974. BD Mérieux would later become bioMérieux.{{Cite web|title=Alain MERIEUX|url=https://francechinafoundation.org/staff/alain-merieux/|access-date=2021-07-27|website=France China Foundation|language=en}} The company expanded its services and offerings through product development, acquisitions and partnerships:
- Api Systems, acquired in 1987{{Cite web|title=bioMérieux 2013|url=https://dokumen.tips/documents/biomerieux-2-013.html|access-date=2021-07-27|website=dokumen.tips|language=en}}
- Vitek Systems, acquired in 1988
- Organon Teknika, acquired in 2001 from Akzo Nobel{{Cite web|title=Akzo Nobel transfers Organon Teknika's diagnostics business to bioMérieux {{!}} AkzoNobel|url=https://www.akzonobel.com/en/for-media/media-releases-and-features/akzo-nobel-transfers-organon-teknika%E2%80%99s-diagnostics-business|access-date=2020-11-03|website=www.akzonobel.com}}
- Bacterial Barcodes, acquired in 2006{{Cite web |url=https://scrip.pharmaintelligence.informa.com/deals/200610151 |title=* :: Scrip |access-date=2017-11-01 |archive-url=https://web.archive.org/web/20171107025412/https://scrip.pharmaintelligence.informa.com/deals/200610151 |archive-date=2017-11-07 |url-status=dead }}
- Biomedics (Spain) and BTF (Australia), acquired in 2007{{Cite web|title=Biomerieux S.A. Acquires BTF Pty. {{!}} Mergr|url=https://mergr.com/biomerieux-s.a.-acquires-btf-pty.|access-date=2020-11-03|website=mergr.com}}
- AB Biodisk (Sweden), AviaraDx (bioTheragnostics today) (USA) and PML Microbiologicals (USA), acquired in 2008{{Cite news|date=2008-12-08|title=BioMerieux buys U.S. microbiology firm|language=en|work=Reuters|url=https://www.reuters.com/article/biomerieux-idINL863440920081208|access-date=2020-11-03}}
- Meikang Biotech and of Shanghai Zenka Biotechnology, acquired in 2010{{Cite web|title=Pharma commercial intelligence, news & analysis {{!}} Evaluate|url=https://www.evaluate.com/|access-date=2020-11-03|website=www.evaluate.com}}
- AES Laboratoire and Argene (France), acquired in 2011{{Cite web|title=BioMérieux Acquires AES Laboratoire|url=https://www.qualityassurancemag.com/article/qa-052011-biomerieux-acquires-aes-laboratoire/|access-date=2020-11-03|website=Quality Assurance & Food Safety|language=en}}
- RAS (India), a specialist in molecular biology, acquired in 2012
- Partnership with Quanterix in 2012 for the development of a new generation of ultrasensitive, multiplex immunoassays.{{Cite web|title=bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays {{!}} Quanterix|url=https://www.quanterix.com/resources/press-releases/biomerieux-and-quanterix-sign-strategic-partnership-ultrasensitive-and|access-date=2020-11-03|website=www.quanterix.com}}
- BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology,{{Cite web|title=BioMerieux Finalizes BioFire Diagnostics Acquisition|url=https://www.genomeweb.com/pcrsample-prep/biomerieux-finalizes-biofire-diagnostics-acquisition|access-date=2020-11-03|website=GenomeWeb|date=16 January 2014 |language=en-us}}{{Cite news|date=2013-09-04|title=BioMerieux buys diagnostics rival BioFire for $450 mln|language=en|work=Reuters|url=https://www.reuters.com/article/biomerieux-biofire-idUSL6N0H014H20130904|access-date=2020-11-03}} acquired in 2014
- BioMerieux molecular biology affiliate BioFire, LLC. opened the Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, Utah{{Cite web|last1=Jun 29|first1=Elaine Sanchez Wilson {{!}}|last2=Diagnostics {{!}} 0 {{!}}|first2=2017 {{!}} Molecular|date=2017-06-30|title=BioFire Opens Center for Molecular Diagnostics|url=https://clpmag.com/instruments-test-kits/molecular-diagnostics/biofire-opens-center-molecular-diagnostics/|access-date=2020-11-03|website=Clinical Lab Product|language=en-US}} in 2017
- Invisible Sentinel, A Philadelphia life sciences company that develops novel technology to quickly detect pathogens in food and beverages including wine and beer.{{Cite web|last=|first=|date=|title=$75 million deal: Invisible Sentinel sold to French biotech company|url=https://www.bizjournals.com/philadelphia/news/2019/02/07/75-million-deal-invisible-sentinel-sold-to-french.html|url-status=live|archive-url=https://web.archive.org/web/20210509085704/https://www.bizjournals.com/philadelphia/news/2019/02/07/75-million-deal-invisible-sentinel-sold-to-french.html |archive-date=2021-05-09 |access-date=2020-11-03|website=www.bizjournals.com}}
Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Bélingard is President, and Alexandre Mérieux is General Director. bioMérieux was listed on the stock exchange in 2004.{{Cite web |url=https://invivo.pharmaintelligence.informa.com/IV002374/bioMerieux-a-FamilyOwned-French-Firm-Finally-Goes-Public |title=BioMerieux, a Family-Owned French Firm, Finally Goes Public :: In Vivo |access-date=2017-11-01 |archive-url=https://web.archive.org/web/20171107020033/https://invivo.pharmaintelligence.informa.com/IV002374/bioMerieux-a-FamilyOwned-French-Firm-Finally-Goes-Public |archive-date=2017-11-07 |url-status=dead }}
Labrador Diagnostics filed a lawsuit against BioFire Diagnostics, a subsidiary of bioMérieux, for patent infringement on March 9, 2020.{{Cite web|url=https://www.cadwalader.com/uploads/media/Labrador_v_BioFire.pdf|title=LABRADOR DIAGNOSTICS V. BIOFIRE DIAGNOSTICS, LLC and BIOMERIEUX S.A.|publisher=IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE}} On March 11, 2020, bioMérieux announced the finalization of their real-time PCR SARS-COV-2 R-GENE test. The company also announced the development of a fully automated test based on the BioFire FilmArray technology with the support of the United States Department of Defense. Lastly, bioMérieux launched development on an expanded version of its BioFire FilmArray Respiratory Panel 2. The new version included SARS-CoV-2 in addition to the 21 other common respiratory pathogens and delivered results in approximately 45 minutes.{{Cite web|url=https://www.biomerieux.com/en/novel-coranovirus-covid-19 |title=First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux|date=March 11, 2020}}{{Cite web|url=https://www.fda.gov/media/137742/download |title=ARGENE® SARS-COV-2 R-GENE®|website=FDA.gov}}{{Cite web|url=https://www.fda.gov/media/137583/download|title=BioFire® Respiratory Panel 2.1 (RP2.1) |website=FDA.gov}} After this announcement, Labrador issued a statement claiming that when it filed the lawsuit against BioFire it had no idea BioFire was developing COVID-19 testing kits.{{Cite web|url=https://www.lifesciencesipreview.com/news/fortress-offers-licences-after-covid-19-testing-patent-backlash-3957|title=Fortress withdraws patent lawsuit over COVID-19 testing discovery|author=Edward Pearcey|website=Life Sciences IP Review}}{{Cite web|url=https://www.businesswire.com/news/home/20200316005955/en/Labrador-Diagnostics-Grant-Royalty-free-Licenses-COVID-19-Testing|title=Labrador Diagnostics Will Grant Royalty-free Licenses for COVID-19 Testing|date=March 17, 2020|website=Business Wire}} Fortress Investment Group, parent company to Labrador, offered to grant both the defendants and anyone else a royalty-free license for its technology for use in COVID-19 tests. bioMérieux and BioFire declined Labrador's offer.
In June 2021, bioMérieux launched EPISEQ SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants. The application identifies variants based on international nomenclatures, including any new variant of concern (VOC), and is compatible with three major sequencing platforms (Illumina, Inc., Oxford Nanopore Technologies, Thermo Fisher Scientific).{{Cite web |url=https://www.selectscience.net/product-news/biomerieux-launches-episeq-sars-cov-2-a-cloud-based-software-application-for-the-epidemiological-surveillance-of-sars-cov-2-variants?artID=55118 |title=First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux |publisher=Select Science|date=June 30, 2021 |access-date=2021-07-27}}
Shareholders
| class="wikitable"
|Nom | |
| Institut Mérieux
|58.9% |
| Groupe Dassault
|4.6% |
| GIMD
|4.6% |
| Sofina
|2.1% |
| Employees
|0.6% |
References
{{Reflist}}
External links
- [http://www.biomerieux.com/ Corporate Website]
- [http://www.biomerieux-finance.com/ Investor website]
- [http://www.biomerieux-usa.com/ bioMerieux USA Website]
- [https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=23790762 Bloomberg Snapshot]
{{CAC Next 20 companies}}
{{DJSI World}}
{{Authority control}}
{{DEFAULTSORT:Biomerieux}}
Category:Biotechnology companies of France
Category:Companies listed on Euronext Paris
Category:Biotechnology companies established in 1963